132 related articles for article (PubMed ID: 35347010)
1. Baseline Modified Glasgow Prognostic Score (mGPS) Predicts Radiologic Response and Overall Survival in Metastatic Hormone-sensitive Prostate Cancer Treated With Docetaxel Chemotherapy.
Neuberger M; Skladny J; Goly N; Wessels F; WEIß C; Egen L; Erben P; GROß-Weege M; Grüne B; Hartung F; Herrmann J; Honeck P; Jarczyk J; Kowalewski KF; Mühlbauer J; Nitschke K; Nientiedt M; Walach MT; Waldbillig F; Westhoff N; VON Hardenberg J; Kriegmair M; Worst TS; Nuhn P
Anticancer Res; 2022 Apr; 42(4):1911-1918. PubMed ID: 35347010
[TBL] [Abstract][Full Text] [Related]
2. Systemic inflammatory biomarkers as predictive and prognostic factors in men with metastatic castration-refractory prostate cancer treated with docetaxel therapy: a comprehensive analysis in a German real-world cohort.
Neuberger M; Goly N; Skladny J; Milczynski V; Weiß C; Wessels F; Nitschke K; Grüne B; Haney CM; Hartung F; Herrmann J; Jarczyk J; Kowalewski KF; Waldbillig F; Kriegmair MC; Westhoff N; Worst TS; Nuhn P
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3371-3381. PubMed ID: 35939112
[TBL] [Abstract][Full Text] [Related]
3. Development of a prognostic model for survival time prediction in castration-resistant prostate cancer patients.
Stangl-Kremser J; Mari A; Suarez-Ibarrola R; D'Andrea D; Korn SM; Pones M; Kramer G; Karakiewicz P; Enikeev DV; Glybochko PV; Briganti A; Shariat SF
Urol Oncol; 2020 Jun; 38(6):600.e9-600.e15. PubMed ID: 31953003
[TBL] [Abstract][Full Text] [Related]
4. Glasgow prognostic score as a prognostic factor in metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy.
Linton A; Pond G; Clarke S; Vardy J; Galsky M; Sonpavde G
Clin Genitourin Cancer; 2013 Dec; 11(4):423-30. PubMed ID: 23816526
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Value of High-Sensitivity Modified Glasgow Prognostic Score in Castration-Resistant Prostate Cancer Patients Who Received Docetaxel.
Ando K; Sakamoto S; Saito S; Maimaiti M; Imamura Y; Sazuka T; Sato N; Komiya A; Anzai N; Ichikawa T
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33673284
[TBL] [Abstract][Full Text] [Related]
6. Staging the Tumor and Staging the Host: Pretreatment Combined Neutrophil Lymphocyte Ratio and Modified Glasgow Prognostic Score Is Associated with Overall Survival in Patients with Esophagogastric Cancers Undergoing Treatment with Curative Intent.
McSorley ST; Lau HYN; McIntosh D; Forshaw MJ; McMillan DC; Crumley AB
Ann Surg Oncol; 2021 Feb; 28(2):722-731. PubMed ID: 32892266
[TBL] [Abstract][Full Text] [Related]
7. Impact of baseline serum IL-8 on metastatic hormone-sensitive prostate cancer outcomes in the Phase 3 CHAARTED trial (E3805).
Harshman LC; Wang VX; Hamid AA; Santone G; Drake CG; Carducci MA; DiPaola RS; Fichorova RN; Sweeney CJ
Prostate; 2020 Dec; 80(16):1429-1437. PubMed ID: 32949185
[TBL] [Abstract][Full Text] [Related]
8. Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients.
Song A; Eo W; Lee S
World J Gastroenterol; 2015 Nov; 21(43):12410-20. PubMed ID: 26604648
[TBL] [Abstract][Full Text] [Related]
9. Modified Glasgow Prognostic Score, Prognostic Nutritional Index and ECOG Performance Score Predicts Survival Better than Sarcopenia, Cachexia and Some Inflammatory Indices in Metastatic Gastric Cancer.
Demirelli B; Babacan NA; Ercelep Ö; Öztürk MA; Kaya S; Tanrıkulu E; Khalil S; Hasanov R; Alan Ö; Telli TA; Koca S; Arıbal ME; Kuzan B; Dane F; Yumuk PF
Nutr Cancer; 2021; 73(2):230-238. PubMed ID: 32270713
[No Abstract] [Full Text] [Related]
10. Lymphocyte to Monocyte Ratio and Modified Glasgow Prognostic Score Predict Prognosis of Lung Adenocarcinoma Without Driver Mutation.
Minami S; Ihara S; Kim SH; Yamamoto S; Komuta K
World J Oncol; 2018 Feb; 9(1):13-20. PubMed ID: 29581811
[TBL] [Abstract][Full Text] [Related]
11. Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients.
Fan L; Wang R; Chi C; Cai W; Zhang Y; Qian H; Shao X; Wang Y; Xu F; Pan J; Zhu Y; Shangguan X; Zhou L; Dong B; Xue W
Prostate; 2018 Mar; 78(4):250-256. PubMed ID: 29285775
[TBL] [Abstract][Full Text] [Related]
12. Changes in neutrophile-to-lymphocyte ratio as predictive and prognostic biomarker in metastatic prostate cancer treated with taxane-based chemotherapy.
Neuberger M; Weiß C; Goly N; Skladny J; Nitschke K; Wessels F; Kowalewski KF; Waldbillig F; Hartung F; Nientiedt M; Egen L; Herrmann J; Jarczyk J; Walach MT; Kriegmair MC; Westhoff N; Worst TS; Nuhn P
Discov Oncol; 2022 Dec; 13(1):140. PubMed ID: 36522513
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of inflammation-based scores in patients receiving radical resection for colorectal cancer.
Wang F; He W; Jiang C; Guo G; Ke B; Dai Q; Long J; Xia L
BMC Cancer; 2018 Nov; 18(1):1102. PubMed ID: 30419863
[TBL] [Abstract][Full Text] [Related]
14. Systemic inflammation and survival of patients with prostate cancer: evidence from the Glasgow Inflammation Outcome Study.
Shafique K; Proctor MJ; McMillan DC; Qureshi K; Leung H; Morrison DS
Prostate Cancer Prostatic Dis; 2012 Jun; 15(2):195-201. PubMed ID: 22343838
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of changes in systemic inflammatory markers and carcinoembryonic antigen levels in predicting metastatic colorectal cancer prognosis and chemotherapy response.
Kim IH; Lee JE; Yang JH; Jeong JW; Ro S; Lee MA
Asia Pac J Clin Oncol; 2018 Jun; 14(3):239-246. PubMed ID: 29044941
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the prognostic value of longitudinal measurements of systemic inflammation in patients undergoing curative resection of colorectal cancer.
Guthrie GJ; Roxburgh CS; Farhan-Alanie OM; Horgan PG; McMillan DC
Br J Cancer; 2013 Jul; 109(1):24-8. PubMed ID: 23799846
[TBL] [Abstract][Full Text] [Related]
17. Prediction of Treatment Response and Survival with Chemotherapy for Metastatic Penile Cancer by the Modified Glasgow Prognostic Score.
Draeger DL; Groh S; Buchholz T; Woehl M; Nolting J; Hakenberg OW
Urol Int; 2023; 107(5):489-495. PubMed ID: 34610603
[TBL] [Abstract][Full Text] [Related]
18. The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy.
Sonpavde G; Pond GR; Berry WR; de Wit R; Eisenberger MA; Tannock IF; Armstrong AJ
Cancer; 2011 Sep; 117(17):3963-71. PubMed ID: 21365623
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of inflammation-based markers for predicting the prognosis of unresectable pancreatic ductal adenocarcinoma treated with chemotherapy.
Asama H; Suzuki R; Takagi T; Sugimoto M; Konno N; Watanabe K; Nakamura J; Kikuchi H; Takasumi M; Sato Y; Irie H; Hikichi T; Ohira H
Mol Clin Oncol; 2018 Oct; 9(4):408-414. PubMed ID: 30233794
[TBL] [Abstract][Full Text] [Related]
20. Patient-reported Quality of Life and Survival Outcomes in Prostate Cancer: Analysis of the ECOG-ACRIN E3805 Chemohormonal Androgen Ablation Randomized Trial (CHAARTED).
Sentana-Lledo D; Chu X; Jarrard DF; Carducci MA; DiPaola RS; Wagner LI; Cella D; Sweeney CJ; Morgans AK
Eur Urol Oncol; 2024 Apr; ():. PubMed ID: 38688766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
